166 related articles for article (PubMed ID: 21906694)
1. The impact of genetic biomarkers on drug and companion diagnostic return on investment.
Keeling P
Drug Discov Today; 2011 Oct; 16(19-20):850-1. PubMed ID: 21906694
[No Abstract] [Full Text] [Related]
2. Patents discipline is key to securing big pharma investment.
Jones N
Drug Discov Today; 2012 Jan; 17(1-2):1-2. PubMed ID: 22138380
[No Abstract] [Full Text] [Related]
3. The economics of personalized medicine: commercialization as a driver of return on investment.
Keeling P; Roth M; Zietlow T
N Biotechnol; 2012 Sep; 29(6):720-31. PubMed ID: 22713855
[TBL] [Abstract][Full Text] [Related]
4. Bank tests drug development waters.
Mullard A
Nat Rev Drug Discov; 2014 Sep; 13(9):643-4. PubMed ID: 25176422
[No Abstract] [Full Text] [Related]
5. Uncommon ventures launch to tackle uncommon diseases.
Dolgin E
Nat Med; 2013 Aug; 19(8):950-1. PubMed ID: 23921728
[No Abstract] [Full Text] [Related]
6. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
Han E; Kim TH; Jeung MJ; Lee EK
Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
[TBL] [Abstract][Full Text] [Related]
7. Funding: Donor drugs.
Willyard C
Nature; 2016 May; 533(7601):S43-5. PubMed ID: 27144609
[No Abstract] [Full Text] [Related]
8. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
9. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.
Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A
Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics and diagnostics.
Persidis A
Nat Biotechnol; 1998 Aug; 16(8):791-2. PubMed ID: 9702782
[No Abstract] [Full Text] [Related]
11. [PHARMACEUTICAL INDUSTRY AND PERSONALIZED MEDICINE: A PARADIGM SHIFT IN THE DEVELOPMENT OF NEW DRUGS].
Scheen AJ
Rev Med Liege; 2015; 70(5-6):237-41. PubMed ID: 26285445
[TBL] [Abstract][Full Text] [Related]
12. Insurers skeptical of usefulness of companion diagnostics.
Manag Care; 2012 Apr; 21(4):49. PubMed ID: 22593857
[No Abstract] [Full Text] [Related]
13. Drug-diagnostic co-development: how to harness the value.
Blair ED; Blakemore JA
Drug Discov Today; 2011 Oct; 16(19-20):902-5. PubMed ID: 21888987
[TBL] [Abstract][Full Text] [Related]
14. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
Halim AB
Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
[TBL] [Abstract][Full Text] [Related]
15. The shrinking of the knowledge base - what is the impact of this on the speed and security of drug development?
Branthwaite P
Drug Discov Today; 2010 Jan; 15(1-2):1-2. PubMed ID: 19837187
[No Abstract] [Full Text] [Related]
16. Brazilian drug companies hope to benefit from foreign investment.
May M
Nat Med; 2011 Oct; 17(10):1171. PubMed ID: 21988977
[No Abstract] [Full Text] [Related]
17. Market watch: industry perspectives on personalized medicine.
Zuckerman R; Milne CP
Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258
[No Abstract] [Full Text] [Related]
18. Is drug discovery dead?
Baldwin JJ
Future Med Chem; 2011 Nov; 3(15):1873-6. PubMed ID: 22023031
[No Abstract] [Full Text] [Related]
19. Drugs and diagnostic innovations to improve global health.
Peeling RW; Nwaka S
Infect Dis Clin North Am; 2011 Sep; 25(3):693-705, xi. PubMed ID: 21896368
[TBL] [Abstract][Full Text] [Related]
20. Drug discovery: a view through the looking glass.
Lenhert S; Vellanti FG
Future Med Chem; 2012 Oct; 4(16):2011-3. PubMed ID: 23157232
[No Abstract] [Full Text] [Related]
[Next] [New Search]
